Staphylococcus species assay
Test in Focus
Staphylococcus argenteus and Staphylococcus schweitzeri are two recently described bacterial species related to Staphylococcus aureus. In this "Test in Focus" episode of the "Answers From the Lab" podcast, Audrey Schuetz, M.D., discusses Mayo Clinic Laboratories' unique PCR assay that identifies these Staphylococcus species.
"Our assay can differentiate Staphylococcus argenteus and Staphylococcus schweitzeri from Staphylococcus aureus. That is unique," Dr. Schuetz says. "Other available methods, even some of the very advanced methods, don't differentiate these species."
Mayo Clinic Laboratories’ assay can clarify whether bacterial colonies contain the recently described Staphylococcus species. "We do not run the assay on direct patient specimens, such as nasal swabs. It's intended for use on isolates when we have an unclear identification of Staphylococcus species," Dr. Schuetz says. "The organism may look like a staph species, but the color might not be quite right. Mass spectrometry, which many of us rely on in the laboratory, might be delivering an unclear reading."
Precise identification and reporting of Staphylococcus species benefit patient care. Clinicians might not be familiar with the newly described species, which — with Staphylococcus aureus — comprise the "Staphylococcus aureus complex."
"Clinicians who don't recognize these newly described organisms might think of them as coagulase-negative staphylococci — which generally aren't as concerning clinically as Staphylococcus aureus," Dr. Schuetz says. "The lab results might not be taken as seriously. Clinicians could end up providing inappropriate or suboptimal treatment."
Listen to learn more about how the IDENT assay can provide more informative results for Staphylococcus testing.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Cherisse Marcou, Ph.D., and Marissa Ellingson, M.S., CGC, discuss whole exome sequencing (WES) at Mayo Clinic Laboratories. The comprehensive evaluation uses next-generation sequencing to detect for single nucleotide variants, small insertions or deletions, and copy number variants on approximately 20,000 genes, enabling precision answers to accurately diagnose, manage, and treat patients with identified inherited illness.
Alicia Algeciras, Ph.D., describes Mayo Clinic Laboratories’ new blood test to detect NFLC, or neurofilament light chain protein. NFLC is a biomarker for several neurodegenerative conditions. The new assay can determine if a patient’s cognitive decline is due to a neurodegenerative condition or some other, reversible condition — while avoiding the need for more-invasive testing of cerebrospinal fluid.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories' unique approach to urine drug testing for addiction rehabilitation. Designed to guide and monitor therapy, the comprehensive profile tests for the most commonly used substances, including alcohol and nicotine, for a complete picture of a patient’s substance use.